Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 19 studies | 27% ± 14% | |
epithelial cell of proximal tubule | 7 studies | 49% ± 11% | |
endothelial cell | 6 studies | 24% ± 8% | |
pericyte | 6 studies | 19% ± 5% | |
epithelial cell | 6 studies | 38% ± 19% | |
astrocyte | 6 studies | 24% ± 7% | |
kidney loop of Henle epithelial cell | 5 studies | 27% ± 6% | |
connective tissue cell | 5 studies | 24% ± 6% | |
ciliated cell | 5 studies | 29% ± 10% | |
kidney distal convoluted tubule epithelial cell | 4 studies | 29% ± 5% | |
enterocyte | 4 studies | 26% ± 5% | |
retinal pigment epithelial cell | 4 studies | 33% ± 17% | |
myofibroblast cell | 4 studies | 20% ± 3% | |
progenitor cell | 3 studies | 17% ± 1% | |
renal alpha-intercalated cell | 3 studies | 25% ± 6% | |
smooth muscle cell | 3 studies | 17% ± 1% | |
intestinal crypt stem cell | 3 studies | 19% ± 2% | |
basal cell | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 2847.20 | 653 / 653 | 100% | 35.31 | 602 / 605 |
kidney | 100% | 4589.36 | 89 / 89 | 99% | 32.00 | 896 / 901 |
breast | 100% | 1925.53 | 459 / 459 | 91% | 10.32 | 1022 / 1118 |
brain | 91% | 1255.40 | 2408 / 2642 | 99% | 21.83 | 696 / 705 |
ovary | 100% | 2334.83 | 180 / 180 | 90% | 7.98 | 386 / 430 |
adrenal gland | 100% | 3464.57 | 258 / 258 | 90% | 13.82 | 206 / 230 |
uterus | 100% | 2034.78 | 170 / 170 | 88% | 9.66 | 405 / 459 |
bladder | 100% | 1649.48 | 21 / 21 | 85% | 8.40 | 430 / 504 |
skin | 100% | 1205.75 | 1807 / 1809 | 85% | 8.95 | 401 / 472 |
lung | 100% | 1453.10 | 577 / 578 | 85% | 7.73 | 979 / 1155 |
pancreas | 92% | 547.32 | 301 / 328 | 92% | 12.34 | 164 / 178 |
stomach | 100% | 1265.92 | 359 / 359 | 77% | 6.29 | 221 / 286 |
intestine | 100% | 1487.59 | 966 / 966 | 73% | 5.84 | 384 / 527 |
liver | 97% | 1521.82 | 219 / 226 | 72% | 6.81 | 294 / 406 |
prostate | 100% | 1680.62 | 245 / 245 | 66% | 5.07 | 333 / 502 |
esophagus | 100% | 1366.62 | 1443 / 1445 | 60% | 4.28 | 110 / 183 |
adipose | 100% | 1783.01 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2031.90 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1002.83 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.04 | 1 / 1 |
heart | 97% | 985.80 | 833 / 861 | 0% | 0 | 0 / 0 |
muscle | 94% | 531.94 | 756 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 5.07 | 24 / 29 |
eye | 0% | 0 | 0 / 0 | 81% | 11.35 | 65 / 80 |
tonsil | 0% | 0 | 0 / 0 | 64% | 4.62 | 29 / 45 |
peripheral blood | 21% | 161.80 | 191 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006635 | Biological process | fatty acid beta-oxidation |
GO_0042168 | Biological process | heme metabolic process |
GO_0019290 | Biological process | siderophore biosynthetic process |
GO_0030855 | Biological process | epithelial cell differentiation |
GO_0006880 | Biological process | intracellular sequestering of iron ion |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0016617 | Molecular function | 4-oxoproline reductase activity |
GO_0051287 | Molecular function | NAD binding |
GO_0016628 | Molecular function | oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor |
GO_0003858 | Molecular function | 3-hydroxybutyrate dehydrogenase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | BDH2 |
Protein name | 3-hydroxybutyrate dehydrogenase 2 Alternative protein BDH2 Dehydrogenase/reductase SDR family member 6 (EC 1.1.1.-) ((R)-beta-hydroxybutyrate dehydrogenase) (3-hydroxybutyrate dehydrogenase type 2) (EC 1.1.1.30) (4-oxo-L-proline reductase) (EC 1.1.1.104) (Oxidoreductase UCPA) (Short chain dehydrogenase/reductase family 15C member 1) Dehydrogenase/reductase SDR family member 6 (EC 1.1.1.104) (EC 1.1.1.30) ((R)-beta-hydroxybutyrate dehydrogenase) (3-hydroxybutyrate dehydrogenase type 2) (4-oxo-L-proline reductase) (Oxidoreductase UCPA) (Short chain dehydrogenase/reductase family 15C member 1) |
Synonyms | DHRS6 UNQ6308/PRO20933 SDR15C1 |
Description | FUNCTION: NAD(H)-dependent dehydrogenase/reductase with a preference for cyclic substrates (By similarity). Catalyzes stereoselective conversion of 4-oxo-L-proline to cis-4-hydroxy-L-proline, likely a detoxification mechanism for ketoprolines . Mediates the formation of 2,5-dihydroxybenzoate (2,5-DHBA), a siderophore that chelates free cytoplasmic iron and associates with LCN2, thereby regulating iron transport and homeostasis while protecting cells against free radical-induced oxidative stress. The iron-siderophore complex is imported into mitochondria, providing an iron source for mitochondrial metabolic processes in particular heme synthesis (By similarity). May act as a 3-hydroxybutyrate dehydrogenase . . |
Accessions | ENST00000509245.1 ENST00000506521.5 ENST00000296424.9 [Q9BUT1-1] L0R823 ENST00000511354.5 D6RFG2 Q9BUT1 D6RBF6 ENST00000504285.5 D6RIR6 D6R9U8 |